BBP418 / ANNUAL
No resting orders on this market.
Important information: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. BBP-418 (also known by its chemical name ribitol) is an experimental oral small-molecule drug being developed by BridgeBio to treat a rare inherited muscle disease called limb-girdle muscular dystrophy type 2I (LGMD2I/R9). Think of it like a missing ingredient in a factory: the disease prevents muscle cells from attaching a critical sugar coating to a key protective protein, and BBP-418 supplies the raw material the factory needs to get that process running again. It is taken orally and was shown in the FORTIFY trial to significantly boost levels of the properly-coated protein in patients, which appears to translate into meaningful improvements in muscle and lung function.
Resolves Yes if the FDA's decision on BBP-418 by Ml Bio Solutions Inc. in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. BBP-418 (also known by its chemical name ribitol) is an experimental oral small-molecule drug being developed by BridgeBio to treat a rare inherited muscle disease called limb-girdle muscular dystrophy type 2I (LGMD2I/R9). Think of it like a missing ingredient in a factory: the disease prevents muscle cells from attaching a critical sugar coating to a key protective protein, and BBP-418 supplies the raw material the factory needs to get that process running again. It is taken orally and was shown in the FORTIFY trial to significantly boost levels of the properly-coated protein in patients, which appears to translate into meaningful improvements in muscle and lung function.